Allarity Therapeutics Reports Improved Financial Results for Q3 2025 with Reduced Net Loss

Allarity Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $2.8 million, a significant improvement compared to a net loss of $11.6 million in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $7.9 million, down from $17.1 million in the prior year. The reduction in losses is attributed to a decrease in total operating expenses, which fell to $2.5 million for the third quarter of 2025 from $12.3 million in the same quarter of 2024, primarily due to the absence of impairment charges related to intangible assets that were recorded in the previous year.

The company’s total operating expenses for the nine months ended September 30, 2025, were $9.7 million, down from $19.9 million in the same period of 2024. Research and development expenses increased to $4.9 million for the nine months ended September 30, 2025, compared to $4.2 million in the prior year, reflecting ongoing investments in the Phase II clinical trial of stenoparib. General and administrative expenses also decreased, totaling $4.8 million for the nine months ended September 30, 2025, down from $6.0 million in 2024, largely due to reduced professional service costs.

In terms of liquidity, Allarity reported cash and cash equivalents of $16.9 million as of September 30, 2025, a decrease from $19.5 million at the end of 2024. The company utilized $11.6 million in cash for operating activities during the first nine months of 2025, compared to $14.1 million in the same period of 2024. The decrease in cash used in operations is attributed to lower net losses and changes in working capital. The company also generated $10.9 million from financing activities, primarily through the sale of common stock, which included proceeds from an at-the-market offering.

Strategically, Allarity has made significant advancements, including the FDA granting Fast Track designation for stenoparib for the treatment of advanced ovarian cancer, which allows for expedited development and review processes. Additionally, the company appointed Jeffrey S. Ervin as Chief Financial Officer on July 1, 2025, following the resignation of Alexander Epshinsky. The company also initiated a share repurchase program, repurchasing 145,061 shares at a cost of approximately $140,000 during the third quarter.

Looking ahead, Allarity anticipates continued investment in the development of stenoparib and other research initiatives. The company expects to incur substantial expenses as it advances its clinical trials and seeks regulatory approvals. While management believes that its current cash reserves will support operations for at least the next 12 months, it acknowledges the need for additional capital to fund ongoing and future projects. The company remains focused on enhancing its operational capabilities and addressing the challenges inherent in the biotechnology sector.